CC Chemokine Ligand 18 in ANCA-Associated Crescentic GN


*III. Medizinische Klinik and Institut für †Klinische Chemie and Institut für ‡Pathologie, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany; ‡Medizinische Klinik III, Uniklinik Rheinisch Westfälische Technische Hochschule, Aachen, Germany; §Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York; †Klinik für Innere Medizin III, Universitätssklinikum Jena, Jena, Germany; †Klinik für Innere Medizin, Vivantes Klinikum im Friedrichshain, Berlin, Germany; **Klinik für Nephrologie und Notfalldiagnostik, Klinikum Dortmund, Dortmund, Germany; ††Abteilung Innere Medizin I, Universitätssklinikum Ulm, Ulm, Germany; ‡‡Abteilung Nephrologie, Klinikum St. Georg, Leipzig, Germany; and ††IV Medizinische Abteilung, Asklepios Klinik Barmbek, Hamburg, Germany

ABSTRACT

ANCA-associated vasculitis is the most frequent cause of crescentic GN. To define new molecular and/or cellular biomarkers of this disease in the kidney, we performed microarray analyses of renal biopsy samples from patients with ANCA-associated crescentic GN. Expression profiles were correlated with clinical data in a prospective study of patients with renal ANCA disease. CC chemokine ligand 18 (CCL18), acting through CC chemokine receptor 8 (CCR8) on mononuclear cells, was identified as the most upregulated chemotactic cytokine in patients with newly diagnosed ANCA-associated crescentic GN. Macrophages and myeloid dendritic cells in the kidney were detected as CCL18-producing cells. The density of CCL18+ cells correlated with crescent formation, interstitial inflammation, and impairment of renal function. CCL18 protein levels were higher in sera of patients with renal ANCA disease compared with those in sera of patients with other forms of crescentic GN. CCL18 serum levels were higher in patients who suffered from ANCA-associated renal relapses compared with those in patients who remained in remission. Using a murine model of crescentic GN, we explored the effects of the CCL18 murine functional analog CCL8 and its receptor CCR8 on kidney function and morphology. Compared with wild-type mice, Ccr8−/− mice had significantly less infiltration of pathogenic mononuclear phagocytes. Furthermore, Ccr8−/− mice maintained renal function better and had reduced renal tissue injury. In summary, our data indicate that CCL18 drives renal inflammation through CCR8-expressing cells and could serve as a biomarker for disease activity and renal relapse in ANCA-associated crescentic GN.


ANCA-associated vasculitis is the major cause of rapidly progressive GN. Despite substantial progress in our understanding of the pathophysiology of the disease, renal outcomes remain poor in a large percentage of patients.1–7 In addition, renal survival has not improved significantly with the application of new therapeutic approaches.8–11 Histopathologic features and the clinical course of the disease are variable, and assessment of disease activity is...
often limited because of the lack of reliable disease-specific biomarkers.

To define new biomarkers of disease activity, we conducted a prospective study in patients with ANCA-associated crescentic GN by analyzing microarrays of renal biopsies from paraffin-embedded tissues. Among a large number of differentially expressed genes, CC chemokine ligand 18 (CCL18) was the most upregulated chemokine in patients with the disease compared with healthy controls. There is substantial evidence that chemokines and their receptors drive renal leukocyte recruitment and thereby, play an important role during the progression of ANCA-associated crescentic GN. Therefore, we investigated whether CCL18 could be a marker for clinical disease activity.

Until recently, a rodent counterpart of human CCL18 had not been identified. In 2013, Islam et al. reported the murine CCL8 (mCCL8) as its functional analog. Both chemokines acted through CC chemokine receptor 8 (CCR8) and were induced in alternatively activated macrophages as well as in similar diseases. Similar cytokine patterns regulated the induction of CCL18 and mCCL8. Therefore, we aimed to investigate the functional role of CCR8 in crescentic GN by analyzing Ccr8−/− mice in an experimental model of murine crescentic GN.

Our results indicate that serum levels of CCL18 reflect the disease activity of ANCA-associated crescentic GN and therefore, might be used as a biomarker of this disease.

RESULTS

Patients with ANCA-Associated Crescentic GN

Ninety-six patients with a diagnosis of ANCA-associated crescentic GN were included in this study; 53 of these patients were proteinase 3 (PR3)-positive, and 43 of these patients were myeloperoxidase (MPO)-positive. The clinical baseline characteristics of the patients are summarized in Table 1. Blood samples were collected from 18 patients every 3 months for a period of 18 months (Figure 1).

<table>
<thead>
<tr>
<th>Clinical Characteristic</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
<td>96</td>
</tr>
<tr>
<td>Age at onset of symptoms</td>
<td>63.3±12.9a</td>
</tr>
<tr>
<td>Men</td>
<td>70 (73)</td>
</tr>
<tr>
<td>ANCA type</td>
<td></td>
</tr>
<tr>
<td>PR3</td>
<td>53 (55)</td>
</tr>
<tr>
<td>MPO</td>
<td>43 (45)</td>
</tr>
<tr>
<td>Renal function at time of diagnosis</td>
<td></td>
</tr>
<tr>
<td>Creatinine clearanceb</td>
<td>34.9±24.5c</td>
</tr>
<tr>
<td>Dialysis dependence</td>
<td>26 (27)</td>
</tr>
</tbody>
</table>

aYears±SD.
bPatients not on dialysis.
cmL/min±SD.

Microarray Analysis Reveals CCL18 as the Most Upregulated Chemokine in ANCA-Associated Crescentic GN

Microarray analyses of renal biopsies were performed. A protocol for RNA isolation was established to obtain large amounts of intact RNA from formalin-fixed, paraffin-embedded (FFPE) samples. RNA of a very high quality was obtained (Supplemental Figure 1A). RNA of sufficient quality for amplification and hybridization was obtained from 30 patients with ANCA-associated crescentic GN and 12 controls (preimplantation kidney biopsies of living or deceased kidney donors). The patient characteristics and clinical data of the group of patients from whom RNA was isolated were not significantly different from those from the remaining patients included in the study (Supplemental Table 1). Biopsies of patients with renal ANCA disease displayed an upregulation of 1310 transcripts and a downregulation of 342 transcripts compared with control biopsies (signal log ratio ≥1.0 or ≤−1.0; corrected P<0.01). Genes that were upregulated 7-fold or higher are shown in Figure 2A. Gene ontology annotation of biologic function showed a strong upregulation of transcripts associated with the immune response (Supplemental Figure 1B). Among these genes, CCL18 was one of the most upregulated transcripts and the most upregulated chemokine in renal ANCA disease (Figure 2B). A 98-fold elevated expression of CCL18 was validated by real-time PCR in 14 patients with ANCA-associated crescentic GN compared with 12 controls (biopsies of living and deceased kidney donors; P<0.05) (Figure 2C). A strong correlation between the expression of CCL18 and other molecules involved in inflammation was observed (Supplemental Table 2).

Localization of CCL18- and CCR8-Expressing Cells in the Kidney by Immunohistochemical Analysis

To localize CCL18- and CCR8-expressing cells in the kidney, immunohistochemistry was performed in 31 renal biopsies of patients with ANCA-associated crescentic GN. CCL18+ cells were identified as infiltrating interstitial mononuclear cells (Figure 3, A and B). Consistent with their morphologic appearance, staining of consecutive sections with CCL18, CD68, and CD209 (dendritic cell [DC]-specific intracellular adhesion molecule-3–grabbing nonintegrin [SIGN]) revealed CCL18+ cells coexpressing CD68 as well as CCL18+ CD68+ cells coexpressing CD209 (Figure 3, C–E). A quantitative analysis identified 34.2%±6.6% of these cells as CCL18+ CD68+ and 17.0%±8.7% of these cells as CCL18+ CD68+ CD209+. Staining of consecutive sections with CCL18, CD3, and CD20 did not reveal CCL18+ cells as CD3+ or CD20+ (data not shown). Immunohistochemistry of renal tissue sections derived from patients with ANCA-associated crescentic GN indicated that CCR8+ mononuclear cells obtain the characteristics of macrophages. Staining of consecutive sections showed single CD68+ cells coexpressing CCR8 (Figure 3, F and G). No coexpression of CCL18 and CCR8 was observed.
Patient characteristics and clinical data did not differ significantly in the group of patients from whom biopsy specimens were analyzed for immunohistochemistry compared with the remaining patients included in the study (Supplemental Table 1). CCL18+ cells were observed predominantly in the inflamed, nonscarred tubulointerstitium. The cells were also found in atrophic tubulointerstitial areas and rarely, the glomeruli. In patients with renal ANCA disease, the density of CCL18+ cells correlated with the mRNA levels of CCL18 (P, 0.01) (Figure 3H). CCL18 mRNA levels correlated with the percentage of cellular crescents (P<0.01) (Figure 3I). The percentage of crescents, including cellular, fibrocellular, and sclerotic crescents, also correlated with the number of CCL18+ cells (P<0.05) (Supplemental Figure 2A). The strongest correlation was found with cellular crescents only (P<0.01) (Figure 3J). Furthermore, the number of CCL18+ cells correlated with the severity of the acute interstitial inflammation (P<0.001) (Figure 3K). The degree of interstitial fibrosis and tubular atrophy (Figure 3L) and the infiltration of T lymphocytes and macrophages did not correlate with the density of CCL18+ cells (Supplemental Figure 2, B and C). The number of CCL18+ cells correlated negatively with the GFR at the time of biopsy (P<0.05) (Figure 3M).

CCL18 Serum Levels Are Elevated in ANCA-Associated Crescentic GN
Serum CCL18 levels in patients with ANCA-associated crescentic GN were significantly higher than those of healthy volunteers and patients with non–ANCA-associated crescentic GN (P<0.001) (Figure 4A). CCL18 serum levels decreased during immunosuppressive treatment and remained low during follow-up (P<0.05) (Figure 4B). The decrease in CCL18 serum levels was even more pronounced when patients were excluded for requiring rescue therapy for disease activity during follow-up (Supplemental Figure 2D). Patients received standard induction therapy with steroids and cyclophosphamide or rituximab. Information on patient outcome is summarized in Figure 1 and Table 2.

CCL18 Serum Levels Are Elevated in Patients with Relapsing ANCA Disease
Renal relapse was determined as initiation of immunosuppressive rescue therapy because of clinical signs of renal disease activity. Renal disease activity was defined as rising serum creatinine and urinary red cell casts or a repeat biopsy with fresh ANCA-associated glomerular lesions. Eleven patients suffered from relapsing renal disease. These patients had higher CCL18 serum levels at the time of biopsy compared with patients who remained in remission during follow-up (P<0.05) (Figure 4C). In four of these patients, a CCL18 serum level was assessed at the onset of relapse (Figure 4, D–G).

CCL18 Serum Levels Do Not Correlate with Serum Levels of ANCA
Correlation analyses were performed between serum levels of CCL18, MPO, and PR3 at the time of study inclusion. Neither positive nor negative correlations were detected (Supplemental Figure 2, E and F). There were also no significant differences in the disease and antibody subgroups, between men and women, or in patients with involvement of other organs (i.e., lung involvement) (Supplemental Figure 2, G–J).

CCR8 Drives the Recruitment of Pathogenic Mononuclear Phagocytes in Experimental Crescentic GN
We evaluated the role of mCCL8 and its receptor CCR8 in a murine model of crescentic GN (nephrotoxic nephritis [NTN]). We analyzed mRNA expression levels during the course of disease. Quantitative RT-PCR of renal cortex samples showed that both CCR8 and CCL8 were highly upregulated (Figure 5A). CCL8 expression was markedly increased from day 5 onward (day 10: 116.5-fold versus the non-nephritic control). The CCR8 mRNA expression level showed a similar increase, with a peak at day 10 (4-fold versus the non-nephritic control). CCL1, the
previously known ligand of CCR8, was also upregulated in the inflamed renal cortex (41-fold versus the non-nephritic control at day 10) (Figure 5A).

Next, we investigated leukocyte infiltration in Ccr8\(^{-/-}\) mice during crescentic GN. Ccr8\(^{-/-}\) mice showed a markedly reduced infiltration of mononuclear phagocytes in the inflamed kidney compared with nephritic wild-type (WT) mice. Immunohistologic staining of F4/80, a glycoprotein expressed by interstitial mononuclear phagocytes, revealed fewer F4/80-expressing cells in the inflamed renal tubulointerstitium in Ccr8\(^{-/-}\) mice (38.5 cells/low-power field) compared with nephritic WT mice (46 cells/low-power field) (Figure 5, B and C). The renal flow cytometry analysis revealed a significantly reduced number of CD11b\(^{+}\) F4/80\(^{+}\) leukocytes in the nephritic renal cortex of Ccr8\(^{-/-}\) mice (23% of CD45\(^{+}\) CD11b\(^{+}\) F4/80\(^{+}\) leukocytes; \(P<0.05\)) (Figure 5, D and E). In contrast, renal CD3\(^{+}\) T cell infiltration and renal Th1, Th17, and Th2 responses were unaltered in nephritic Ccr8\(^{-/-}\) mice (Supplemental Figure 3). Quantification of mouse anti-sheep IgG subclasses in the serum of nephritic WT, Ccr8\(^{-/-}\), and non-nephritic WT control mice revealed an unchanged humoral immune response in Ccr8\(^{-/-}\) mice (Supplemental Figure 4).

Mononuclear phagocytes within the inflamed kidney comprise a heterogeneous group of inflammatory and regulatory cells. Therefore, we aimed to functionally characterize the significantly altered population of CD11b\(^{+}\) F4/80\(^{+}\) cells. Intra-cellular staining of the proinflammatory cytokine TNF-\(\alpha\) was conducted in leukocytes isolated from nephritic WT kidneys (Figure 5F). CD11b\(^{+}\) F4/80\(^{+}\) cells had a greater capacity to produce TNF-\(\alpha\) compared with the CD45\(^{+}\) CD11b\(^{-}\) F4/80\(^{-}\) control cells.

**Figure 2.** Microarray analysis shows CCL18 as the highest upregulated transcript among all chemokines in ANCA-associated crescentic GN. (A) Heat map of differentially regulated transcripts in ANCA-associated crescentic GN compared with control kidneys. The RNA from 30 patients with ANCA-associated crescentic GN and 12 controls (preimplantation kidney biopsies of living or deceased kidney donors) was used for the microarray analyses. Total RNA was isolated from FFPE renal biopsies. Transcripts shown in this heat map had a signal log ratio of 2.3 and \(-2.3\) and were considered differentially expressed. Each column represents one biopsy sample, and each row shows the results for one probe set per transcript. Blue indicates downregulation of the probe sets, and red indicates upregulation of the probe sets. Areas in white represent no regulation. (B) Summary of the chemokines assessed. The unique identification number (UID) is indicated for each sample. A signal log ratio (SLR) of 3.41 was obtained for CCL18. (C) Quantitative real-time PCR analysis confirmed the high level of CCL18 expression. Total RNA from FFPE kidney biopsies was examined for CCL18 expression (Hs00268113_m1; Life Sciences) in relation to the levels of 18S RNA (Hs03928985_g1; Life Sciences). Renal CCL18 expression was 98 times higher in ANCA-associated crescentic GN (\(n=14\)) compared with controls (\(n=12\)). Bars represent means±SDs. *\(P<0.05\).
population, which suggested that these cells possessed a proinflammatory phenotype (Figure 5G).

**CCR8 Promotes Renal Tissue Injury in Experimental Crescentic GN**

NTN was induced in Ccr8−/− and WT mice. At day 8, Ccr8−/− mice showed significantly less tubulointerstitial and glomerular injury compared with control animals (Figure 6, A–C). The level of BUN was reduced in nephritic Ccr8−/− mice compared with nephritic WT mice at day 8 (P<0.005) (Figure 6D). Albuminuria was increased in both nephritic groups; however, there was no significant difference among the groups (Figure 6E).

**Adoptively Transferred Monocytes Restore Kidney Injury in Nephritic Ccr8−/− Mice**

Adoptive transfer was performed as previously described.24 WT CD45+CD115+ bone marrow-derived monocytes were adoptively transferred into WT or Ccr8−/− mice. NTN was induced after 24 hours, and the results were analyzed at day 8. Renal FACS analysis did not reveal differences in the quantification of CD11b+ F4/80+ mononuclear phagocytes between WT and Ccr8−/− mice (Figure 6, F and G). In addition, analysis of tubulointerstitial damage and glomerular injury revealed no differences in nephritic Ccr8−/− mice compared with nephritic mice (Figure 6, H and I).

**DISCUSSION**

Crescentic GN caused by ANCA-associated vasculitis is an aggressive and destructive

mRNA correlated with the density of CCL18+ cells (n=15). (J) The CCL18 mRNA levels correlated with the percentage of cellular crescents (n=12). (K) The percentage of cellular crescents correlated with the number of CCL18+ cells (n=31). (L) The density of CCL18+ cells correlated with the degree of acute interstitial inflammation (n=31). (M) The number of CCL18+ cells did not correlate with interstitial fibrosis and tubular atrophy (IFTA; n=31). (N) The density of the CCL18+ cells correlated with impairment of renal function (GFR) in patients who did not receive immunosuppressive treatment before renal biopsy (n=24).
A disease that often causes end stage renal failure. Studies in rodent models and humans have shown that T cells, macrophages, and DCs play a central role in the development and progression of proliferative and crescentic GN.23,25–33 Chemokines and their receptors have been identified as key regulators of leukocyte migration12 and therefore, might be an interesting therapeutic target or biomarker in patients with ANCA-associated crescentic GN.

Microarray analysis of kidney biopsies from patients with ANCA-associated crescentic GN revealed CCL18 as the most upregulated among all of the chemokine transcripts in renal tissues. CCL18 was originally detected in human fetal lung tissue and is mainly expressed by alternatively activated macrophages and DCs.14,34,35 Enhanced CCL18 production together with elevated CCL18 serum levels have been reported in several inflammatory disorders and various cancers.15,36 CCL18 has been proposed as a marker for disease activity37 and shown to correlate with poor outcome in certain diseases.37–40 Although some data indicate that CCL18 might act on immature DCs and T lymphocytes,15,41–43 investigation of the biologic effects of CCL18 has been largely hampered by the lack of a known CCL18 receptor. The recent identification of CCR8 as the major receptor of CCL18 has permitted the functional evaluation of CCL18 and its murine analog CCL8.13

In our study, immunohistochemical analysis revealed the presence of CCL18 in intrarenal cells with a mononuclear appearance. Consecutive sections identified macrophages and myeloid DCs25 coexpressing CCL18. The density of intrarenal CCL18+ cells correlated with the crescent formation, the degree of interstitial inflammation, and the impairment of renal function at the time of biopsy. Therefore, intrarenal mononuclear CCL18+ cells, which are present during acute inflammation and damage in ANCA-associated crescentic GN, might be either generated by or initiating and driving the disease process. This observation is supported by the strong correlation between CCL18 expression and the expression of other molecules involved in inflammation in renal tissue of patients with ANCA-associated crescentic GN. The number of myeloid DCs has been shown to correlate with increased serum creatinine in proliferative GN.25 Consistently, the density of CCL18+ cells correlated with impairment of renal function in renal ANCA disease.

Because the density of CCL18+ cells in renal biopsies was associated with acute but not chronic kidney damage, we measured CCL18 serum levels to assess whether the chemokine levels correlated with disease activity or severity. CCL18 serum Figure 4. CCL18 serum levels are elevated in ANCA-associated crescentic GN. (A) CCL18 serum levels were compared among patients with ANCA-associated crescentic GN (ANCA GN), patients with non-ANCA GN, and healthy volunteers (controls). The levels of CCL18 were determined by ELISA. CCL18 serum levels were markedly elevated in patients with ANCA GN (n=63) compared with patients with non-ANCA GN (n=6) and healthy controls (n=10). CCL18 serum levels did not differ among patients with non-ANCA GN and healthy volunteers. (B) CCL18 serum levels were measured during follow-up. CCL18 serum levels decreased during the initial immunosuppressive treatment with cyclophosphamide or rituximab and remained low during the maintenance therapy with azathioprine. The CCL18 measurements obtained at the time of diagnosis (n=63) and 6 (n=31), 12 (n=24), and 18 months of follow-up are shown (n=18). (C) At the time of biopsy, CCL18 levels were significantly higher in patients who experienced a renal relapse during follow-up (n=10) compared with those who remained in remission (n=53). (D–G) Longitudinal study with serum measurements of CCL18 in patients suffering from renal relapsing disease. Arrows indicate the onset of relapse. Bars represent means±SDs. *P<0.05; **P<0.01; ***P<0.001.
levels were significantly higher in patients with renal ANCA disease compared with patients suffering from non–ANCA-associated crescentic GN. CCL18 serum levels decreased during the 6 months of immunosuppressive induction treatment and remained low during follow-up, which indicated that CCL18 levels might reflect disease activity. Patients suffering from disease relapses had significantly higher CCL18 levels at the time of diagnosis. In four of these patients, CCL18 serum levels were assessed at onset of relapse and showed a rise at that time, further supporting this hypothesis. Therefore, CCL18 might serve as a marker of relapsing and persistent disease and might help to guide immunosuppressive treatment.

CCR8 has been recently discovered as a human receptor for CCL18.13 This chemokine receptor is expressed on Th2 and regulatory T cells as well as on monocytes/macrophages.44–47 We identified macrophages as CCR8-expressing cells in the kidneys of patients with renal ANCA disease as the renal target cell of CCL18. Immunohistochemistry did not reveal macrophages coexpressing CCL18 and CCR8, and we conclude that CCL18-producing cells and cells expressing CCR8 are two different cell populations.

Identification of CCR8 as a chemokine receptor for CCL18 as well as CCL8 as its murine analog enabled us to study the biologic function of this chemokine and its receptor in a murine model of crescentic GN. The model of NTN does not represent human renal ANCA disease in all aspects of its pathophysiology, but it is the most widely studied mouse model of crescentic GN. CCR8 and mCCL8 were upregulated in the kidneys of nephritic mice. Most importantly, nephritic Ccr8−/− mice had a reduced infiltration of renal mononuclear phagocytes and developed less severe crescentic GN with respect to renal function and renal tissue injury. The adoptive transfer study with Ccr8−/− mice receiving WT bone marrow-derived monocytes showed the importance of CCR8 for the renal mononuclear phagocyte infiltration. Because of the lack of male Ccr8−/− mice, we were not able to transfer CCR8−/− monocytes into nephritic CCR8−/− mice. Therefore, the explanatory power of the transfer experiment is limited, because it misses a control group.

In addition to CCL8, CCL1 (another ligand of CCR8) was found to be upregulated in nephritic kidneys of rodents. Despite that CCL1 upregulation was markedly inferior to CCL8 expression, we cannot claim an exclusive role for CCL8 in driving GN through CCR8 in mice. However, because CCL1 is not upregulated in human ANCA-associated crescentic GN, we highly assume that mCCL8 might reflect the target of interest in rodents, which mimics best the effects that CCL18 drives during human GN.

Our data suggest that CCL18-secreting mononuclear cells might either attract monocytes by CCR8 and/or induce their differentiation into alternatively activated macrophages in renal ANCA disease. Through this mechanism, CCL18+ cells could potentially be responsible for the acute cellular tissue inflammation in crescentic GN.

Our results indicate that the CCL18/CCR8 axis might play an important role in the recruitment of pathogenic mononuclear phagocytes in ANCA-associated crescentic GN. This hypothesis is on the basis of the upregulation of CCR8 as well as the murine CCL18 analog mCCL8 in experimental crescentic GN and the observation that Ccr8−/− mice display an ameliorated course of the disease. In summary, our data indicate that determination of the CCL18 level may support diagnosis and treatment decisions by clinicians for patients with ANCA-associated renal disease.

### CONCISE METHODS

#### Study Design

The goal of this study was to define new molecular or cellular biomarkers in the kidney that indicate clinical outcomes in renal ANCA disease. In total, 96 patients with ANCA-associated crescentic GN with a diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis were included in this prospective observational study. The non-ANCA GN control group comprised patients with a diagnosis of crescentic necrotizing GN caused by antiglomerular basement membrane disease (n=2), lupus (n=1), or IgA nephritis (n=3). Between March of 2009 and January of 2013, patients were recruited from 10 centers in Germany. Prospectively established inclusion criteria were as follows: (1) a rapid decline in renal function, (2) ANCA detected in the sera, and (3) necrotizing and crescentic GN in the kidney biopsy. The trial was performed in accordance with the Declaration of Helsinki. After informed consent was obtained, patient data, sera, and renal biopsies were collected according to the guidelines of the respective local ethics committees.

#### Data Collection

All of the patient data were collected prospectively, starting from the date of trial entry. Long-term follow-up data were acquired from a questionnaire filled in by physicians who participated in the trial. Additional necessary information concerning the patients’ clinical status, renal function, infections, and other adverse events was obtained from discharge letters, including laboratory results and other electronically preserved documentation. The participating physicians performed disease assessments regularly every 3 months during the trial.

#### Entry Parameters

The baseline characteristics assessed were patient’s age, sex, diagnosis, ANCA subtype, serum creatinine, eGFR, proteinuria, BP, and medication, including immunosuppressive treatment.

#### Table 2. Clinical outcome of the patients after 18 months follow-up

<table>
<thead>
<tr>
<th>Outcome</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESRD</td>
<td>10 (10)</td>
</tr>
<tr>
<td>Renal relapse</td>
<td>11 (11)</td>
</tr>
<tr>
<td>Death</td>
<td>13 (14)</td>
</tr>
</tbody>
</table>

www.jasn.org
Figure 5. CCR8 drives the recruitment of pathogenic mononuclear phagocytes in crescentic GN. (A) RT-PCR analysis of renal CCL1, CCL8, and CCR8 mRNA expression during the course of nephritis (n=5–6). The mRNA expression is indicated as the x-fold change compared with non-nephritic WT controls. Symbols represent means±SDs. (B and C) Representative immunohistochemical photographs and quantification of renal tubulointerstitial leukocyte infiltration in nephritic WT, nephritic Ccr8<sup>-/-</sup>, and WT control mice at day 8 after induction of nephritis using the macrophage marker F4/80 (magnification, ×200; WT control, n=4; nephritic WT and nephritic Ccr8<sup>-/-</sup>, n=9). Bars represent means±SDs. (D) Representative FACS analysis of isolated renal leukocytes stained for the mononuclear phagocyte marker F4/80 from nephritic WT, Ccr8<sup>-/-</sup>, and WT control mice at days 8 and 9 of nephritis. Plots were pregated on CD45<sup>+</sup>, CD11b<sup>+</sup>, and Ly6G<sup>+</sup> myelomonocytic leukocytes and are representative of three independent experiments. (E) Quantification of mononuclear phagocytes from the FACS analysis (WT control, n=3; nephritic WT and nephritic Ccr8<sup>-/-</sup>, n=5). Bars represent means±SDs. (F) FACS analyses of renal CD11b<sup>+</sup> F4/80<sup>+</sup> cells isolated from controls and nephritic kidneys at day 8. Cells were pregated on CD45<sup>+</sup> leukocytes. Neutrophils were excluded from the analysis by negatively selecting for CD45<sup>+</sup>, CD11b<sup>+</sup>, and Ly6G<sup>+</sup> cells. Cells were restimulated with lipopolysaccharides and stained intracellularly for TNF-α. (G) The histogram shows TNF-α staining of CD11b<sup>+</sup> F4/80<sup>+</sup> cells or CD45<sup>+</sup> CD11b<sup>-</sup> cells as indicated. qPCR, quantitative PCR. *P<0.05.
Isolation of RNA and cDNA Amplification

Total RNA was isolated from five 8-μm-thick sections of FFPE kidney biopsies using the High Pure FFPE RNA Micro Kit (Roche; Deutschland Holding GmbH, Grenzach-Wyhlen, Germany) with a modified protocol (Supplemental Material). The RNA concentration was determined using a NanoDrop spectrophotometer, and the RNA quality was controlled using an Agilent Bioanalyzer. Fifty nanograms nondegraded RNA (Supplemental Material) was used as a template for reverse transcription. The WT-Ovation FFPE RNA Amplification System V2 (NuGEN, Leek, The Netherlands) was used for cDNA amplification according to the manufacturer’s instructions.

Microarray Analyses

Fragmentation and labeling of amplified cDNA was performed using the Encore Biotin Module (NuGEN) according to the manufacturer’s instructions. Four micrograms labeled cDNA was used to prepare the hybridization mix (Affymetrix, High Wycombe, UK). Samples were hybridized to Affymetrix U133 Plus 2.0 (Affymetrix) microarrays for 17 hours. Fragmentation, labeling, and hybridization were performed according to the protocol provided by the Encore Biotin Module (NuGEN). The data were published in the ArrayExpress database under accession number E-MTAB-1944.

Real-Time RT-PCR Analyses

Total RNA derived from kidney biopsies was used as a template for reverse transcription. The reaction was performed using 0.1 μg RNA, 100 ng/μl random hexamer primer (Invitrogen, Darmstadt, Germany), 10 mmol/L deoxyribonucleotide triphosphates (Invitrogen), and 200 units RevertAid Reverse Transcription (Fermentas GmbH, St. Leon-Rot, Germany). For cDNA synthesis, RNA and primer were incubated for 5 minutes at 65°C. Next, a 15 μl mixture of enzyme, buffer, and deoxyribonucleotide triphosphate was added to the RNA and primer to a final volume of 20 μl. The samples were incubated for 10 minutes at 25°C, 60 minutes at 42°C, and 10 minutes at 70°C. The real-time PCR reaction was performed using the Step One Plus Real-Time PCR System (Applied Biosystems, Foster City, CA) and validated primer pairs for CCL18 (Hs00268113_m1; Life Sciences). The assay was performed in triplicate. The expression of the CCL18 transcripts was quantified against the housekeeping gene 18S ribosomal.
RNA (Hs03928985_g1; Life Sciences) using validated primer pairs. Real-time PCR was performed according to the protocol provided by the manufacturer. Total RNA was prepared according to standard laboratory methods. Real-time PCR was performed in a Step One Plus Real-Time PCR System (Applied Biosystems). All of the samples were run in duplicate and normalized to 18S ribosomal RNA to account for small variabilities in RNA and cDNA content.

ELISAs

Serum samples were collected at the time of biopsy and then every 3 months. Blood samples, which were used as controls, were collected one time after informed consent was obtained. Serum levels of CCL18 (DY394; R&D Systems, Abingdon, UK), anti-MPO antibodies (ORG 519; Vententec, Mainz, Germany), and anti-PR3 antibodies (ORG 618; Vententec) were determined by ELISA according to the protocol provided by the manufacturers, with slight modifications for the CCL18 ELISA (Supplemental Material).

Immunohistochemistry

The FFPE tissue sections were stained for CCL18, CD68, DC-SIGN, CCR8, CD3, and CD20. For CCL18 (500-P108; Preprotech) and CD68 (M0814; Dako, Glostrup, Denmark), the sections were pretreated with a protease solution for 15 minutes at 37°C. For DC-SIGN (yDCN46; BD Biosciences Pharmigen, San Diego, CA), sections were treated in 0.1 M citrate buffer to retrieve antigen. CCR8 (NLS3847; Novus Biologicals, Littleton, CO) staining was performed after treatment in 0.1 M buffer solution to retrieve antigen (S1699; Dako) at pH 6. The sections were incubated with anti-CCL18 (1:200) and anti-CD68 (1:400) antibodies overnight at 4°C. Sections stained with anti–DC-SIGN (1:500), and anti-CCR8 (1:500) antibodies were incubated for 30 minutes at 37°C. Sections stained for CCL18, DC-SIGN, and CCR8 were developed using the POLAP-AP (Zytomed, –DCN46; Berlin, Germany). To detect CD68 staining, ABC-AP (Vector Laboratories, Burlingame, CA) was used. Staining of consecutive sections was performed, because double staining immunohistochemistry was technically not feasible because of different pretreatments of antibodies.

Histopathologic Evaluations

Periodic acid–Schiff and Giemsa staining were applied for renal histopathologic evaluations using light microscopy. Slides were examined by a nephropathologist who was blinded to the patient’s data and research results. The degree of interstitial fibrosis and tubular atrophy was assessed. To further determine the inflammatory infiltrate, the interstitial inflammation was estimated analog to the BANFF classification.49

Animals

Ccr8–/– mice were generated by Chensue et al.50 These mice displayed an aberrant T helper type 2 cell response and impaired eosinophil recruitment in vivo.50 All of the mice were raised under specific pathogen-free conditions. Animal experiments were performed according to national and institutional animal care and ethical guidelines and approved by local ethics committees.

Induction of Crescentic GN (NTN) and Functional Studies

NTN was induced in 8- to 10-week-old male C57BL/6 WT or gene-deficient mice by intraperitoneal injection of 0.5 ml nephrotoxic sheep serum per mouse as previously described.51 For urine sample collection, mice were housed in metabolic cages for 6 hours. Urinary albumin excretion was determined by standard ELISA analysis (Mice-Albumin Kit; Bethyl, Montgomery, TX), whereas urinary creatinine and BUN were measured using standard laboratory methods.

Murine Morphologic Analyses

Light microscopy and immunohistochemistry were performed using routine methods. Crescent formation was assessed in 50 glomeruli per mouse in a blinded fashion in periodic acid–Schiff-stained paraffin sections. As a measure for tubulointerstitial injury, the interstitial area was estimated by point counting of four independent areas of renal cortex per mouse under low magnification (×200) as previously described.52 Two-μm-thick paraffin-embedded sections were stained with antibodies against the monocyte/macrophage cell markers F4/80 (BM8; BMA) and MAC-2 (M3/38; Cedarslane, Burlington, ON, Canada), the T cell marker CD3 (A0452; Dako), or sheep IgG (Jackson Immunoresearch Laboratories) and mouse IgG (Jackson Immunoresearch Laboratories) staining was performed after treatment with the Vectastain ABC-AP Kit (Vector Laboratories). MAC-2+ and CD3+ cells in 30 glomerular cross-sections as well as F4/80+ and CD3+ cells in 30 tubulointerstitial high-power fields (magnification, ×400) were counted per kidney in a blinded manner using light microscopy. Glomerular deposition of mouse IgG and sheep IgG was scored from zero to three in 30 glomeruli per mouse.

Isolation of Leukocytes from the Kidney and Spleen

For leukocyte isolation from murine kidneys, we used previously described methods.51 In brief, kidneys were finely minced and digested for 45 minutes at 37°C with 0.4 mg/ml collagenase D (Roche, Mannheim, Germany) supplemented with 10% heat-inactivated FCS (Invitrogen). Spleens were minced for the splenocyte isolation. Both cell suspensions were sequentially filtered through 70- and 40-μm nylon meshes and washed in HBSS without Ca2+ and Mg2+ (Invitrogen). Cells were washed with HBSS and resuspended in FCS-containing buffer. Cell viability was assessed by trypan blue staining before flow cytometry or cell transfer experiments.

Flow Cytometry

For FACS analysis, renal leukocyte suspensions were stained for 20 minutes at 4°C with the following fluorochrome-conjugated antibodies: CD45 (30-F11), CD11b (M1/70), CD11c (HL3), F4/80 (BM8), CD3 (506A2), and CD4 (XMG1.2; BD Biosciences, Franklin Lakes, NJ; eBioscience, San Diego, CA; or R&D Systems, Minneapolis, MN). Staining of intracellular TNF-α (MP6-XT22; BioLegend, San Diego, CA), IL-17A (TC11–18H10.1; BioLegend), IL-4 (11B11; Santa Cruz Biotechnology, Heidelberg, Germany), and IFN-γ (XMG1.2; BioLegend) was performed –/– with the Vectastain ABC-AP Kit (Vector Laboratories). MAC-2+ and CD3+ cells in 30 glomerular cross-sections as well as F4/80+ and CD3+ cells in 30 tubulointerstitial high-power fields (magnification, ×400) were counted per kidney in a blinded manner using light microscopy. Glomerular deposition of mouse IgG and sheep IgG was scored from zero to three in 30 glomeruli per mouse.

Isolation of Leukocytes from the Kidney and Spleen

For leukocyte isolation from murine kidneys, we used previously described methods.51 In brief, kidneys were finely minced and digested for 45 minutes at 37°C with 0.4 mg/ml collagenase D (Roche, Mannheim, Germany) supplemented with 10% heat-inactivated FCS (Invitrogen). Spleens were minced for the splenocyte isolation. Both cell suspensions were sequentially filtered through 70- and 40-μm nylon meshes and washed in HBSS without Ca2+ and Mg2+ (Invitrogen). Single-cell suspensions were separated using Percoll density gradient (70% and 40%) centrifugation. The leukocyte-enriched cell suspension was aspirated from the Percoll interface. After the erythrocytes had been removed using lysis solution (139 mM NH4Cl and 19 mM Tris), cells were washed with HBSS and resuspended in FCS-containing buffer. Cell viability was assessed by trypan blue staining before flow cytometry or cell transfer experiments.

Flow Cytometry

For FACS analysis, renal leukocyte suspensions were stained for 20 minutes at 4°C with the following fluorochrome-conjugated antibodies: CD45 (30-F11), CD11b (M1/70), CD11c (HL3), F4/80 (BM8), CD3 (506A2), and CD4 (XMG1.2; BD Biosciences, Franklin Lakes, NJ; eBioscience, San Diego, CA; or R&D Systems, Minneapolis, MN). Staining of intracellular TNF-α (MP6-XT22; BioLegend, San Diego, CA), IL-17A (TC11–18H10.1; BioLegend), IL-4 (11B11; Santa Cruz Biotechnology, Heidelberg, Germany), and IFN-γ (XMG1.2; BioLegend) was performed.
eBioscience) was performed as previously described. In brief, cells were activated by incubation at 37°C with 5% CO₂ for 4 hours with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma-Aldrich, St. Louis, MO) and ionomycin (1 μg/ml; Calbiochem-Merck, Darmstadt, Germany) or 1 μg/ml lipopolysaccharide (only for intracellular TNF-α staining) in X-VIVO medium (Lonza AG, Walkersville, MD). After a 30-minute incubation, Brefeldin A (10 μg/ml; Sigma-Aldrich) was added. Dead cells were stained (LIVE/DEAD Fixable Read Dead Stain Kit; Invitrogen), and samples were acquired using a Becton & Dickinson LSRII System with Diva software. Data analysis was performed using Flow Jo software (Tree Star Inc., Ashland, OR).

Adaptive Monocyte Transfer
For the adoptive monocyte transfer, previously described methods were used. In brief, monocytes were purified from mouse bone marrow by immunomagnetic selection of CD115⁺ cells using a CD115 biotin (BD Biosciences) antibody followed by a streptavidin magnetic assisted cell sorting conjugate (Miltenyi Biotec). The purity of the isolated monocytes was checked by flow cytometry and found to be 82.4%. Intravenous injection of 1.5×10⁶ cells into WT and Ccr8⁻/⁻ recipients was performed 24 hours before induction of NTN. Mice were euthanized after 8 days.

Assessment of Humoral Nephritogenic Immune Responses
Mouse anti-sheep IgG antibody titers were measured by ELISA using sera collected 10 days after induction of nephritis as previously described. IgM and IgG titers were measured using the Ready-Set-Go ELISA according to the manufacturer’s instructions (Bioscience, San Diego, CA).

Statistical Analyses
Microarrays were background-corrected and normalized using the Robust Multi-array Average procedure and quantile normalization, respectively. The results were corrected for multiple testing using the bootstrapping procedure. A signal log ratio ≥1.0 or ≤-1.0 and a corrected P<0.01 were considered to indicate statistical significance. Differences between two groups were compared using a two-tailed t test. In the case of multiple comparisons, one-way ANOVA with Bonferroni multiple comparisons test was performed using GraphPad Prism software. Comparison of CCL18 serum levels from patients with ANCA-associated crescentic GN and controls as well as the time course of CCL18 serum levels were conducted using the Kruskal–Wallis test. Correlation analyses of CCL18 serum levels and the density of CCL18⁺ cells were performed using Spearman’s rank correlation. P<0.05 was considered statistically significant.

ACKNOWLEDGMENTS
We thank Saskia Schröder, Catharina Verkooyen, Annett Peters, Ursula Kneissler, and Mariola Reszka for their excellent technical assistance. We thank the study nurses Samaneh Liagos, Birgit Goldmann, Eugen Kinzer, and Daniela Bergerle for their thorough and dedicated collection of clinical data.

This work was supported by Deutsche Forschungsgemeinschaft Grants PA 754/7-2 (to U.P.), KFO 228:STA193/9-1 (to R.A.K.S.), and KFO 228:STA193/9-2 (to R.A.K.S.).

Participating physicians include Martin Kuhlmann from Vivantes Klinikum im Friedrichshain, Berlin, Germany, Peter J. Heering from Städtisches Klinikum Solingen, Solingen, Germany, Dirk Bokemeyer from Augusta-Kranken-Anstalt, Bochum, Germany, and Andre Schneider from Marienhaus Klinikum, Neuwied, Germany.

DISCLOSURES
None.

REFERENCES


This article contains supplemental material online at http://jasn.asnjournals.org/lookup/suppl/doi:10.1681/ASN.2014040407/-/DCSupplemental.